Princeton BioPharma
 
 

ABOUT US


MICHAEL WELLS
CHAIRMAN AND CEO


GEORGE PARISE
CHIEF FINANCIAL OFFICER


BARRY LEVINSON, PhD
CHIEF BUSINESS AND SCIENTIFIC OFFICER

Michael Wells
MICHAEL WELLS
CHAIRMAN AND CEO

Michael has over 20 years of experience in the pharmaceutical industry with an excellent track record of forming and growing new enterprises. Prior to forming Princeton BioPharma, he was the founder and CEO of Aton Pharma, Inc., a specialty pharmaceutical company with a portfolio of products focused on rare diseases. The company grew from $11 million in sales in 2006 to nearly $100 million in sales in 2010 with products selling in over 30 countries. Based on these efforts he was a recipient of the Ernst & Young Entrepreneur of the Year Award in 2009. In 2010 the company was acquired by Valeant Pharmaceuticals for $330 million.

Prior to forming Aton, Michael co-founded Lathian Systems Inc., a venture backed company that provides online data and marketing services to pharmaceutical and biotech companies. His career began at Merck & Co. Inc., where he held positions ranging from hospital sales to brand management.

He holds both a Bachelor's and Master's of Science from the University of Pittsburgh and a MBA from The Wharton School. He is also a Managing Director for Princeton BioPharma Capital Partners, LLC, a private equity firm that invests in commercial stage health care companies. Michael also currently serves on two boards, Covis Pharma S.à.r.l and Curaseal.

 

Michael Wells
GEORGE PARISE
CHIEF FINANCIAL OFFICER

George brings strong experience from the pharmaceutical industry and in the private equity sector. Prior to co-founding Princeton BioPharma, George was the Chief Financial Officer of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology.

His prior experience includes executive operating roles with Cerberus Capital, leading diligence efforts and assuming key operating roles within portfolio companies.

During his tenure with Cerberus, George's positions included Chief Financial Officer of Velocita Wireless, where he led the complex standalone transition of this Cingular Wireless carve-out and spearheaded the eventual successful sale to Sprint. George has held Senior Executive positions at CAI Wireless and CellularVision and began his career with Ernst & Young.

George is also a Managing Director for Princeton BioPharma Capital Partners, LLC, a private equity firm that invests in commercial stage health care companies and serves on the board of Covis Pharmaceuticals, Inc.

George holds a BS in Accounting from Seton Hall University and is a CPA (inactive).

 

Michael Wells
BARRY LEVINSON, PhD
CHIEF BUSINESS AND SCIENTIFIC OFFICER

Dr. Levinson has over 30 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining PBCP, he was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Barry was a founding employee of Aton Pharma, Inc. As its Vice President of Business Development, he identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton's products to new medical uses, and spearheaded R&D programs to develop these new indications.

Before Aton, Barry was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (d/b/a Apeiron Partners), a boutique life sciences strategic advisory group and prior to CPP a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Barry held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (d/b/a Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering's Office of Technology. Before Berlex, he initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company's Radiation Safety Officer.

Dr. Levinson received his PhD and Master's degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his Bachelor of Arts, with highest honors, in Biochemistry from Princeton University. In addition to his roles in Princeton BioPharma, Barry is a Managing Director of Princeton BioPharma Capital Partners LLC, a private equity firm that invests in commercial stage health care companies and serves on the board of Covis Pharma S.à.r.l